What is ZyVersa Therapeutics Inc.?
, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 801.50K.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.